Alloy Therapeutics, Inc.’s Post

Using Native SEC-MS to quantitate aggregates Analyze monoclonal antibodies (mAbs) and mAb-derived therapeutics using Agilent native SEC/MS. Download guide: https://lnkd.in/eHYyKwxh #advancebio #mAbs

Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec

Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis

Streamline your IND submission by generating RCBs and IND-ready documentation in as little as 9 weeks from transfection. SUREmAb from KBI Biopharma streamlines monoclonal antibody development to accelerate your program, making development success a SURE thing. Learn more: https://hubs.la/Q02cx_l00

If you are attending the National Biotechnology Conference next month in San Fran, be sure to check out Vera Bretton's poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison. Vera's expertise helps many clients navigate the research and development hurdles for biologics. Check out the link below to learn more about some of the projects her team supports here at Prolytix!

Going to NBC? Be sure to check out Vera Bretton’s poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison as an Alternative to Spiking Studies. Learn more about our Antibody Analytical Capabilities here: https://lnkd.in/eQDcApdC #BioA, #Prolytix, #AAPS

Interested in GPCRs drug discovery? Watch this OnDemand webinar for an overview on GPCRs and novel studies implementing ꞵ-Arrestin Recruitment & GTP Gi Binding Assays for enhancing your therapeutics research.http://ms.spr.ly/60429Ji8k

The hotly anticipated 2nd RNA Assay Development & Screening Summit returns to Boston, August 20-22, 2024, to revolutionize RNA-targeted drug discovery with robust assays and screens. Check out the Brand-New Event Guide here: https://ter.li/zuknlg Don’t miss your opportunity to see expert talks with industry leaders from AstraZeneca, Arrakis Therapeutics, Biogen, NextRNA Therapeutics, Accent Therapeutics, Inc. , Atavistik Bio and many more, at the industry's first and only conference dedicated to supporting in-house assay development and screening strategies for discovering selective RNA-targeting small molecules. #RNAtargeting #RNA #smallmolecules #drugdiscovery #assaydevelopment #assay #screening

Join in the discussion about how enzymatic synthesis will improve quality and scale for the production of therapeutic oligonucleotides.